Selected Publication

2025年

• Hiraga H, Machida R, Kawai A, Kunisada T, Yonemoto T, Endo M, Nishida Y, Nagano A, Ae K, Yoshida S, Ananuma K, Toguchida J, Furuta D, Nakayama R, Akisue T, Hiruma T, Morii T, Nishimura H, Hiraoka K, Takeyama M, Emori M, Hatano H, Kawashima H, Isu K, Tanaka K, Kataoka T, Fukuda H, Iwamoto Y, Ozaki T

  Comparison of Methotrexate, Adriamycin and Cisplatin (MAP) versus MAP + Ifosfamide (MAPIF)in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (JCOG0905): a multicentre, open-label, randomised controlled trial.

  J Clin Oncol, Online ahead of print, doi: 10.1200/JCO-24-01281. 2025.

2024年

• Sun H, Kawano M, Iwasaki T, Itonaga I, Kubota Y, Tsumura H, Tanaka K

  MicroRNA-329-3p inhibits the Wnt/β-catenin pathway and proliferation of osteosarcoma cells by targeting transcription factor 7-like 1.

  Oncol Res, 32(3):463-476. doi: 10.32604/or.2023.044085. 2024

2023年

• Kawano M, Tanaka K, Itonaga I, Iwasaki T, Kubota Y, Tsumura H

  Tumor-suppressive microRNA-152 inhibits the proliferation of Ewing’s sarcoma cells by targeting CDK5R1.

  Sci Rep, 13(1):18546. doi: 10.1038/s41598-023-45833-6. 2023 (Correspondence)

• Kawano M, Tanaka K, Itonaga I, Iwasaki T, Kubota Y, Tsumura H

  The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells.

  Oncol Res, 31(5): 631-643, 2023 (Correspondence)

2022年

• Kubota Y, Tanaka K, Kawano M, Iwasaki T, Itonaga I, Tsumura H

  Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma.

  Sci Rep, 12(1):19381. doi: 10.1038/s41598-022-23944-w. 2022 (Correspondence)

• Nishida M, Terabayashi T, Matsuoka S, Okuma T, Adachi S, Tomo T, Kawano M, Tanaka K, Tsumura H, Anai H, Ishizaki T, Nishida Y, Hanada K

  Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition.

  Commun Biol, 5(1):982. doi: 10.1038/s42003-022-03920-w. 2022.

• Acem I, van Houdt WJ, Grünhagen DJ, van der Graaf WTA, Rueten-Budde AJ, Gelderblom H, Verhoef C; PERSARC research group (Tanaka K), van de Sande MAJ.

  The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.

  Eur J Cancer, 165:71-80. doi: 10.1016/j.ejca.2022.01.013. 2022.

• Tanaka K, Suzuki K, Miyashita K, Wakasa K, Kawano M, Nakatsu Y, Tsumura H, Yoshida MA, Oda S

  Activation of recombinational repair in Ewing sarcoma cells carrying EWS-FLI1 fusion gene by chromosome translocation.

  Sci Rep, 12(1):14764. doi: 10.1038/s41598-022-19164-x. 2022. (Correspondence)

• Tanaka K, Machida R, Kawai A, Nakayama R, Tsukushi S, Asanuma K, Matsumoto Y, Hiraga H, Hiraoka K, Watanuki M, Yonemoto T, Abe S, Katagiri H, Nishida Y, Nagano A, Suehara Y, Kawashima H, Kawano M, Morii T, Hatano H, Toguchida J, Okuma T, Takeyama M, Takenaka S, Akisue T, Furuta T, Emori M, Hiruma T, Outani H, Yamamoto T, Kataoka T, Fukuda H, Ozaki T, Iwamoto Y

  Perioperative adriamycin plus ifosfamide versus gemcitabine plus docetaxel for patients with high-risk soft tissue sarcomas: A randomized, open-label, phase II/III study.

  Br J Cancer, 127(8):1487-1496. doi: 10.1038/s41416-022-01912-5. 2022. (Correspondence)

2021年

• Kawano M, Iwasaki T, Itonaga I, Kubota Y, Tanaka K, Tsumura H

  Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma.

  Sci Rep, 11(1):18099. doi: 10.1038/s41598-021-97153-2. 2021 (Correspondence)

• Inoue N, Terabayashi T, Takiguchi-Kawashima Y, Fujinami D, Matsuoka S, Kawano M, Tanaka K, Tsumura H, Ishizaki T, Narahara H, Kohda D, Nishida Y, Hanada K

  The benzylisoquinoline alkaloids, berberine and coptisine, act against camptothecin-resistanttopoisomerase I mutants.

  Sci Rep, 11(1):7718. doi: 10.1038/s41598-021-87344-2. 2021

2020年

• Tanaka K, Kawano M, Iwasaki T, Matsuda S, Itonaga I, Tsumura H

  Surrogate endpoints for overall survival in randomized controlled trials of localized osteosarcoma: A meta-analytic evaluation.

  Sci Rep, 10(1):8573. doi: 10.1038/s41598-020-65591-z. 2020 (Correspondence)

• Acem I, Verhoef C, Rueten-Budde AJ, Grünhagen DJ, van Houdt WJ, van de Sande MAJ; PERSARC study group (Tanaka K).

  Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients.

  Eur J Cancer, 141:128-136. doi: 10.1016/j.ejca.2020.09.021. 2020

2018年

• Kawano M, Tanaka K, Iwasaki T, Itonaga I, Tsumura H

  Interaction between human osteosarcoma and mesenchymal stem cells via an interleukin-8 signaling loop in the tumor microenvironment.

  Cell Commun Signal, 16(1):13. doi: 10.1186/s12964-018-0225-2, 2018 (Correspondence)

• He B, Chiba Y, Li H, de Vega S, Tanaka K, Yoshizaki K, Ishijima M, Yuasa K, Ishikawa M, Rhodes C, Sakai K, Zhang P, Fukumoto S, Zhou X, Yamada Y.

  Identification of the novel tooth-specific transcription factor AmeloD.

  J Dent Res, 2018:22034518808254. doi: 10.1177/0022034518808254. 2018

• Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H

  microRNA-181c prevents apoptosis by targeting of FAS receptor in Ewing's sarcoma cells.

  Cancer Cell Int, 18:37. doi:10.1186/s12935-018-0536-9. 2018 (Correspondence)

2017年

• Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H

  microRNA-20b promotes cell proliferation via targeting of TGF-β receptor II and up-regulates MYC expression in Ewing’s sarcoma cells.

  Int J Oncol, 51(6):1842-1850, doi: 10.3892/ijo.2017.4155. 2017 (Correspondence)

2016年

• Tanaka K, Kawano M, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S, Tsumura H

  Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing’s sarcoma cells.

  Int J Oncol, 48(3):1135-1144, doi: 10.3892/ijo.2016.3317. 2016

• Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H

  MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing’s sarcoma cells.

  Int J Oncol, 48(4):1531-1540, doi: 10.3892/ijo.2016.3379. 2016 (Correspondence)

2015年

• Iwasaki T, Tanaka K, Kawano M, Itonaga I, Tsumura H

  Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells.

  Int J Oncol, 46(4):1543-1550, doi: 10.3892/ijo.2015.2867. 2015 (Correspondence)

• Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T, Tsumura H

  microRNA-93 promotes cell proliferation via targeting of PTEN in osteosarcoma cells.

  J Exp Clin Cancer Res, 34:76, doi:10.1186/s13046-015-0192-z. 2015 (Correspondence)

2010年

• Li Y, Tanaka K, Fan X, Nakatani F, Li X, Nakamura T, Takasaki M, Yamamoto S, Iwamoto Y

  Inhibition of transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing family of tumors.

  Cancer Let, 294:57-65, 2010

2007年

• Sakimura R, Tanaka K, Yamamoto S, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Li Y, Iwamoto Y

  The effects of histone deacetylase inhibitors on the induction of differentiation in Chondrosarcoma cells.

  Clin Cancer Res, 13:275-282, 2007 (Correspondence)

• Li Y, Tanaka K, Li X, Okada T, Nakamura T, Takasaki M, Yamamoto S, Oda Y, Tsuneyoshi M, Iwamoto Y

  Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing’s family tumor cells.

  Int J Cancer, 121:1212-1218, 2007 (Correspondence)

• Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y

  The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing’s family tumor cells.

  Int J Oncol, 31:803-811, 2007 (Correspondence)

• Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, Tanaka K, Tsuchiya H, Matsumine A, Yabe H

  Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.

  Cancer, 109:767-775, 2007

2006年

• Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y

  Involvement of p-glycoprotein and MRP1 in resistance to the cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing’s sarcoma cells.

  Int J Cancer, 118:90-97, 2006 (Correspondence)

• Matsunobu T, Tanaka K, Nakamura T, Nakatani F, Sakimura R, Hanada M, Li X, Okada T, Oda Y, Tsuneyoshi M, Iwamoto Y

  The possible role of EWS-Fli1 in evasion of senescence in Ewing’s family tumors.

  Cancer Res, 66:803-811, 2006 (Correspondence)

• Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M

  CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis.

  Mod Pathol, 19:738-745, 2006

2005年

• Li X, Tanaka K, Nakatani F, Matsunobu T, Sakimura R, Hanada M, Okada T, Nakamura T, Iwamoto Y

  Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing’s family tumor.

  Int J Cancer, 116:385-394, 2005 (Correspondence)

• Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Iwamoto Y

  Antitumor effects of histone deacetylase inhibitor on Ewing’s family tumors.

  Int J Cancer, 116:784-792, 2005 (Correspondence)

• Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozuka Y, Tamiya S, Tanaka K, Matsuda S, Yokoyama R, Iwamoto Y, Tsuneyoshi M

  Frequent alteration of p16INK4a/p14ARF and p53 pathways of round cell appearance in myxoid/round cell liposarcoma: Altered p53 gene and reduced p14ARF expression correlates with poor prognosis.

  J Pathol, 207:410-421, 2005

2004年

• Saito T, Oda Y, Kawaguchi K, Sugimachi K, Yamamoto H, Tateishi N, Tanaka K, Matsuda S, Iwamoto Y, Ladanyi M, Tsuneyoshi M

  E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma.

  Oncogene, 23:8629-8638, 2004

• Matsunobu T, Tanaka K, Matsumoto Y, Nakatani F, Sakimura R, Hanada M, Li X, Oda Y, Naruse I, Hoshino H, Miura H, Tsuneyoshi M, Iwamoto Y

  The prognostic and therapeutic relevance of p27Kip1 in Ewing’s family tumors.

  Clin Cancer Res, 10: 1003-1012, 2004 (Correspondence)

• Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M

  Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk. A comparison of clinicopathological and immunohistochemical features.

  Histopathology, 45:29-38, 2004

2003年

• Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X, Hanada M, Okada T, Iwamoto Y

  Idenitfication of p21(WA1/CIP1) as a direct target of EWS-Fli1 oncogenic fusion protein.

  J Biol Chem, 278: 15105-15115, 2003 (Correspondence)

• Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M

  PTEN/MMAC1 gene mutationis a rare event in soft tissue sarcomas without specific balanced translocations.

  Int J Cancer, 104: 175-178, 2003

• Ayyanathan K, Lechner MS, Bell P, Maul GG, Schultz DC, Yamada Y, Tanaka K, Torigoe K, Rauscher III FJ

  Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation.

  Genes & Development, 17:1855-1869, 2003

2002年

• Saito T, Matsuda S, Tanaka K, Iwamoto Y

  Possible association between higher -catenin mRNA expression and mutated -catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan PCR.

  Lab Invest, 82: 97-103, 2002

• Matsumoto Y, Tanaka K, Hirata G, Hanada M, Shuto T, Yukihide Iwamoto Y

  Possible involvement of the VEGF-Flt-1-FAK pathway in chemotaxis and cell proliferation of osteoclast precursor cells in arthritic joints.

  J Immunol, 168: 5824-5831, 2002

• Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M

  APC mutations in synovial sarcoma.

  J Pathol, 196: 445-449, 2002

• Kuratomi Y, Nomizu M, Tanaka K, Ponce LM, Komiyama S, Kleinman HK, Yamada Y

  Laminin g1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells.

  Br J Cancer, 86: 1169-1173, 2002

2001年

• Sakamoto A, Oda Y, Adachi T, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M

  H-ras oncogene mutation in dedifferentiated liposarcoma:Polymerase chain reaction-restriction fragment length polymorphism analysis.

  Am J Clin Pathol, 115: 235-242, 2001

• Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y,Tsuneyoshi M

  H-ras oncogene mutation in dedifferentiated chondrosarcoma: Polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues.

  Modern Pathol, 14: 343-349, 2001

• Matsumoto Y, Tanaka K, Nakatani F, Matsunobu M, Matsuda S, Iwamoto Y

  Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G1 regulatory genes.

  Br J Cancer, 84: 768-775, 2001

• Saito S, Oda Y, Tanaka K, Matsuda S, Tamiya T, Iwamoto Y, Tsuneyoshi M

  β-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumors.

  J Pathol, 195: 222-228, 2001

• Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M

  E-Cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.

  Am J Pathol, 159: 2117-2124, 2001

• Oda Y, Sakamoto A, Saito T, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M

  Secondary malignant giant cell tumor of bone; molecular abnormalities of p53 and H-ras gene correlated with malignant transformation.

  Histopathology, 39: 629-637, 2001

2000年

• Liu Y, Li H, Tanaka K, Tsumaki N, Yamada Y

  Identification of an enhancer sequence within the first intron required for cartilage-specific transcription of the 2(XI) collagen gene.

  J Biol Chem, 275: 12712-12718, 2000

1999年

• Tsumaki N, Tanaka K, Arikawa-Hirasawa E, Kimura T, Thomas JT, Luyten FP, Yamada Y

  Role of CDMP-1 in skeletal morphogenesis: promotion of mesencymal cell recruitment and chondrocyte differentiation.

  J Cell Biol, 144: 161-173, 1999

1998年

• Kim WH, Nomizu M, Song SY, Tanaka K, Kuratomi Y, Kleinman HK, Yamada Y

  Laminin-alpha1-chain sequence Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg (LQVQLSIR) enhances murine melanoma cell metastasis.

  Int J Cancer, 77: 632-639, 1998

• Tsumaki N, Kimura T, Tanaka K, Kimura JH, Ochi T, Yamada Y

  Modular arrangement of cartilage- and neural tissue-specific cis-elements in the mouse 2(XI) collagen promoter.

  J Biol Chem, 273: 22861-22864, 1998

1997年

• Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y

  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

  J Clin Invest, 99: 239-247, 1997 (Correspondence)

1996年

• Ito Y, Iwamoto Y, Tanaka K, Okuyama K, Sugioka Y

  A quantitative assay using basement membrane extracts to study tumour angiogenesis in vivo.

  Int J Cancer, 67: 148-152, 1996

• Iwamoto Y, Nomizu M, Yamada Y, Ito Y, Tanaka K, Sugioka Y

  Inhibition of angiogenesis, tumor growth and experimental metastasis of human fibrosarcoma cells HT1080 by a multimeric form of the laminin sequence Tyr-Ile-Gly-Ser-Arg (YIGSR).

  Br J Cancer, 73: 589-595, 1996

1995年

• Tanaka K, Iwamoto Y, Noguchi Y, Oda Y, Sugioka Y

  The establishment and characterization of a peripheral neuroepithelioma cell line in soft tissue of extremity.

  Lab Invest, 72: 237-248, 1995 (Correspondence)

• Tanaka K, Iwamoto Y, Ito Y, Ishibashi T, Nakabeppu Y, Sekiguchi M, Sugioka Y

  Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080.

  Cancer Res, 55: 2927-2935, 1995 (Correspondence)